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Research
AbstrACt
Objectives To examine and compare the prevalence of 
coronary artery calcification (CAC) and the frequency of 
cardiac events in a background population and a cohort 
of patients with non-specific chest pain (NSCP) who 
present to an emergency or cardiology department and are 
discharged without an obvious reason for their symptom.
Design A double-blinded, prospective, observational 
cohort study that measures both CT-determined CAC 
scores and cardiac events after 1 year of follow-up.
setting Emergency and cardiology departments in the 
Region of Southern Denmark.
subjects In total, 229 patients with NSCP were compared 
with 722 patients from a background comparator 
population.
Main outcomes measures Prevalence of CAC and 
incidence of unstable angina (UAP), acute myocardial 
infarction (MI), ventricular tachycardia (VT), coronary 
revascularisation and cardiac-related mortality 1 year after 
index contact.
results There was no significant difference in the 
prevalence of CAC (OR 0.9 (95% CI 0.6 to 1.3), P=0.546) 
or the frequency of cardiac endpoints (P=0.64) between 
the studied groups. When compared with the background 
population, the OR for patients with NSCP for a CAC 
>100 Agatston units (AU) was 1.0 (95% CI 0.6 to 1.5), 
P=0.826. During 1 year of follow-up, two (0.9%) patients 
with NSCP underwent cardiac revascularisation, while 
none experienced UAP, MI, VT or death. In the background 
population, four (0.6%) participants experienced a clinical 
cardiac endpoint; two had an MI, one had VT and one had 
a cardiac-related death.
Conclusion The prevalence of CAC (CAC >0 AU) among 
patients with NSCP is comparable to a background 
population and there is a low risk of a cardiac event in the 
first year after discharge. A CAC study does not provide 
notable clinical utility for risk-stratifying patients with 
NSCP.
trial registration number NCT02422316; Pre-results.
IntrODuCtIOn
Cardiovascular disease (CVD) is a major 
public health problem and the most 
common cause of death among men and 
women in Europe and the USA.1–3 Less 
than one in five patients presenting to the 
emergency department with chest pain have 
acute myocardial infarction (MI).4 5 Other 
potential causes for their symptoms include 
non-ischaemic cardiac disease (aneurysm, 
aortic dissection or pulmonary embolism) 
and non-cardiac disease (respiratory, gastro-
intestinal or musculoskeletal disorders). 
However, for a significant number of patients 
the cause of symptoms is unclear and such 
patients are defined as having non-specific 
strength and limitations of this study
 ► The patients were unselected.
 ► The patients were included from six hospitals.
 ► The number of participants was relatively small.
 ► No patients were lost to follow-up.
 ► Few events occurred during follow-up.
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chest pain (NSCP).6 For these patients, the exclusion 
of acute MI in an acute care setting does not rule out 
underlying coronary artery disease (CAD) or the asso-
ciated risk of future cardiac events, as demonstrated by 
studies showing that 0.8%–2.1% of patients evaluated 
for MI and discharged from emergency departments 
have an adverse cardiac outcome in the first 30 days 
after discharge.7 8 
Up to 20% of patients with CAD do not have the tradi-
tional CVD risk factors of hypertension, hyperlipidaemia, 
diabetes or smoking.9 Consequently, there is a need to 
identify diagnostic tools that can be used to risk-strati-
fying patients with chest pain, particularly in an acute care 
setting. A non-contrast cardiac CT can be used to measure 
the presence and extent of coronary artery calcification 
(CAC) and might serve as one such tool. As a diagnostic 
test, it offers the advantages of easy performance, simple 
interpretation and high reproducibility, while exposing 
patients to relatively low levels of radiation.10–13 While it 
has been evaluated as a risk stratification tool in asymp-
tomatic individuals, and demonstrated a CAC prevalence 
of 44%–50%,14 15 its role in patients with NSCP remains 
uninvestigated.
In order to evaluate the role of non-contrast cardiac 
CT as a risk stratification tool for patients with NSCP, this 
study had two goals. The first was to identify the preva-
lence of CAC among patients with NSCP discharged from 
emergency and cardiology departments, and compare 
these findings with observations from an asymptomatic 
background population. The second was to examine 
the frequency of clinical cardiac events in patients with 
NSCP during a 12-month follow-up period and compare 
that data with results from an asymptomatic background 
population and from a population of higher-risk patients 
with NSCP who are referred for further cardiac testing 
after index contact.
MethOD AnD MAterIAls
study design
The study was a double-blinded, prospective, observa-
tional cohort study. It included patients from emergency 
and cardiology departments in the Region of Southern 
Denmark, specifically in the cities of Odense, Svend-
borg, Vejle, Kolding, Aabenraa and Sonderborg. Patients 
were enrolled between September 2014 and May 2015 
provided they met the following inclusion criteria: they 
presented to hospital with acute chest pain and a suspi-
cion of cardiac ischaemia; they were admitted to hospital; 
they had at least one troponin measurement; they were 
discharged with a diagnosis of observation for MI or chest 
pain (International Classification of Diseases,  10th Revi-
sion codes: DR072/DR073/DR034/DR035); and there 
was no identifiable cause for their chest pain. An addi-
tional inclusion criterion was the presence of at least one 
known risk factor for CAD (current smoker, hyperten-
sion, hypercholesterolaemia, diabetes mellitus or signif-
icant family history of CVD).
Patients were excluded from the study if they were 
referred for outpatient cardiac imaging test after the index 
visit, lived outside the catchment area (Region of Southern 
Denmark), were unable to speak Danish, declined to either 
complete a telephone interview and/or undergo a CT scan, 
or had a previous history of CAD as defined by previous MI 
or coronary revascularisation (figure 1).
study population
The study population was identified by performing a 
daily search of troponin values in the central biochem-
ical laboratory, which stores results for the Region of 
Southern Denmark. Electronic patient files for any emer-
gency or cardiology department patients between the 
ages of 30 years and 70 years were reviewed, and patients 
with normal troponin values, as defined by a high sensi-
tivity troponin T ≤14 ng/L or a high sensitivity troponin 
I <25 ng/L, were assessed for study eligibility. Provided 
they met eligibility criteria, they completed a structured 
telephone questionnaire within 3 days of discharge from 
index contact. Thereafter, consent forms and study infor-
mation were sent out. Those patients who returned the 
consent form were scheduled for a non-contrast CT scan, 
the results of which were blinded to participants and 
investigators until the conclusion of the study.
For comparison purposes, we used the Danish Risk Score 
study (DanRisk) population15 as a background compar-
ator group. The DanRisk study population included 1257 
asymptomatic subjects, aged 50–60 years, who were exam-
ined in one of four cardiac CT centres in the Region of 
Southern Denmark (Odense, Esbjerg, Vejle or Svendborg). 
From this study population, we excluded asymptomatic 
individuals without risk factors for CAD (hypertension, 
hypercholesterolaemia, familiar disposition, known smoker 
and diabetes mellitus), individuals with known CAD and 
those missing CAC scores. The remaining group of individ-
uals comprised the comparator group.
Definitions
Comorbidity in the NSCP population was self-reported. 
Individuals were considered to have diabetes mellitus 
if they used an antidiabetic medication or had been 
given a diagnosis of diabetes mellitus by their general 
practitioner. Similarly, hypertension and hypercho-
lesterolaemia were considered present if participants 
used medications to treat either disease or if they had 
received a diagnosis of either illness. Family history was 
defined as a first-degree relative with CVD regardless 
of age of onset, while smoking was defined by current 
smoking status. The first blood pressure and heart rate 
values taken during the index admission were retrieved 
from patient files. Cholesterol values were collected up 
to 3 months before and 3 months after the index admis-
sion, with the value closest to the index date selected for 
the study. Body mass index (BMI) was calculated based 
on self-reported height and weight.
In the background comparator group, individuals were 
considered to have diabetes mellitus, hypertension or 
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hypercholesterolaemia if they used an antidiabetic, hyper-
tension or cholesterol-lowering medication, respectively. 
Family history was defined by the presence of CVD in a 
male first-degree relative <55 years or a female first-degree 
relative <65 years. Smoking was based on smoking status at 
the time the study was conducted. Blood pressure, heart 
rate, BMI and cholesterol values were measured during 
baseline examination.
troponins
Troponin I, used by Odense University Hospital, was anal-
ysed using the Abbot Diagnostics Architect with an upper 
Figure 1 Flow chart for the inclusion of patients with non-specific chest pain. CAD, coronary artery disease; CD, cardiology 
department; CVD, cardiovascular disease; ED, emergency department.
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reference limit of 99th percentile for 24 ng/L and a coef-
ficient variation of <10% at 5 ng/L. The decision limit for 
MI was set at ≥25 ng/L.
Troponin T, used by the other participating hospitals, 
was analysed by Roche Diagnostic Elecsys 2010, modular 
analytics E170, Cobas e411 and Cobas e601. The 99th 
percentile upper reference limit was 14 ng/L, with a coef-
ficient variation of <10% at 13 ng/L and a decision limit 
for MI set at >14 ng/L.
Cardiac Ct protocol
CAC was measured by summing the scores for calcific 
foci in the coronary arteries and then expressing the 
total calcium burden in Agatston units (AU).10 CAC was 
assessed by trained radiographers. In an additional 52 
subjects, the CAC score was reanalysed by the first author.
Two centres used a dual-source CT scanner (SOMATOM 
Definition Flash, Siemens Healthcare, Forchheim, 
Germany) with prospective ECG triggering. In partici-
pants with a heart rate <75 beats per minute (bpm), ECG 
triggering was set during the diastolic phase at 65%–75% 
of the cardiac R–R interval, while in persons with a heart 
rate ≥75 bpm ECG triggering was set during the systolic 
phase at 250–400 ms. Additional CT settings included 
the following: sequential prospective scan, slice thickness 
3 mm, collimation 128×0.6 mm, gantry rotation time 0.28 
ms, 120 kV tube voltage and 90 mAs/rotation.
One centre used a GE 64-slice CT scanner (Discovery 
750 HD; GE Healthcare, Chicago, Illinois, USA). In indi-
viduals with heart rates <75 bpm, ECG triggering was set 
in diastolic phase at 75% of the cardiac R–R interval, and 
in those with heart rates ≥75 bpm, it was set in the systolic 
phase at 40% of the cardiac R–R interval. Other settings 
in this centre included: sequential prospective scan, slice 
thickness 2.5 mm, collimation 64×0.625 mm, gantry rota-
tion time 0.35 ms, 120 kV tube voltage and a 200 mA tube 
current.
Finally, one centre used a Toshiba Aquillion ONE CT 
scanner (Toshiba Medical systems, Japan) with prospec-
tive ECG triggering. If the heart rate was <75 bpm, then 
ECG triggering was in the diastolic phase at 65%–75% of 
the R–R interval and if the heart rate was ≥75 bpm, then 
ECG triggering was set in the systolic phase at 40%. Addi-
tional settings were: sequential prospective scan, slice 
thickness 0.5 mm, collimation 0.5 mm×240–320, gantry 
rotation time 0.275 ms and 120 kV tube voltage.
Follow-up
The study was double blinded with a 12-month follow-up. 
Neither participants nor investigators knew the results of 
the CAC score until the end of follow-up, at which time 
participants and their general practitioner received a 
letter with the results of testing.
The clinical endpoints at follow-up were unstable 
angina (UAP), non-fatal MI, ventricular tachycardia 
(VT), coronary revascularisation and cardiac death. The 
endpoints were compared with the control population 
and with NSCP patients who were referred for cardiac 
imaging testing at the index admission, but who conse-
quently did not participate in the study.
sample size
A sample size calculation was performed before the study. 
The prevalence of an elevated CAC score (CAC >0 AU) 
in the DanRisk comparator population was 44%.15 We 
assumed that the prevalence of CAC scores in our symp-
tomatic low-risk population would be 18% higher (or 
62%), since previous studies found that 79% of symptom-
atic individuals referred for coronary angiography have 
a CAC >0 AU.16 Using the Fleiss method, we calculated 
that we required a sample size of at least 238 patients if 
we were to detect a risk factor with an OR of at least 2.1, a 
significance level of 95%, a power of 80% and a ratio of 1 
for exposed/non-exposed.
statistical analyses
Categorical variables are presented with frequency tables 
and percentages with the distributions of continuous vari-
ables evaluated by empirical histograms. Normally distrib-
uted continuous variables are presented as mean and SD 
values, whereas skewed distributed continuous variables 
are presented with their median and IQR. Fischer’s exact 
test and the χ2 test were used for categorical variables, a 
t-test was used to compare normally distributed variables 
and the Wilcoxon’s rank-sum test was used for skewed 
distributed variables. Patients with NSCP and the control 
population were compared using a multivariate analysis 
that included traditional CVD risk factors (gender, age, 
smoking, hypertension, hypercholesterolaemia, diabetes 
mellitus, a family history of CVD and BMI), the preva-
lence of CAC (the dependent variable) >0 and CAC ≥100. 
The correlation coefficient was 99%. Analyses were 
performed with STATA SE 14. A two-sided P value <0.05 
was considered statistically significant.
ethics
The study protocol was approved by the Regional Scientific 
Ethical Committee for Southern Denmark (S-20140055) 
and conducted in accordance with the Declaration of 
Helsinki. Written informed consent was obtained from 
participating individuals. 
The DanRisk protocol was approved by the Regional 
Scientific Ethical Committee for Southern Denmark 
(S-20080140) and was conducted in accordance with the 
Declaration of Helsinki. Written informed consent was 
obtained from participating individuals. 
results
In total, there were 4289 patients, aged 30–70 years old, 
who were seen in either an emergency or cardiology 
department, and who had at least one troponin measure-
ment. Among these patients, 3047 were not assessed 
for study eligibility on the basis of one or more criteria 
(see figure 1). Of the remaining 1241 patients, 800 were 
assessed for study eligibility, but excluded based on the 
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presence of one or more exclusion criteria. From the 
residual 441 patients, 229 participated in the study and 
underwent a cardiac CT scan, while the remaining 212 
patients, who were classified as non-participants, either 
declined study participation or failed to undergo a 
cardiac CT scan.
Comparing participants with non-participants, it can 
be seen that the mean age was respectively 57 years 
(95% CI 56 to 58) and 52 years (95% CI 50 to 53), with 
a P=0.001. Significantly more participants had hyper-
cholesterolaemia and a family history of CVD compared 
with non-participants, while no significant differences 
were found in gender, diabetes, hypertension or smoking 
status (table 1).
Figure 2 shows the selection of the control group. Of 
the 1825 randomly selected individuals 50 or 60 years 
old who were invited to participate in the DanRisk study, 
there were 1257 who accepted the invitation. Based on 
the criteria established for this study, a total of 535 indi-
viduals were excluded from participation, of whom 513 
did not fulfil the inclusion criteria of having at least one 
risk factor, 16 patients had known CAD and 6 did not 
have a CAC score. The background comparison group 
was thus composed of the residual 722 individuals.
Table 2 lists the characteristics of patients with NSCP 
and the background comparison group. Mean age for the 
NSCP population was 57 years, compared with 55 years 
for the DanRisk group (P=0.007). A significantly higher 
proportion of patients with NSCP had known hypercho-
lesterolaemia and a family history of CVD, while more 
participants in the comparison group were smokers. 
Furthermore, significant differences were found between 
the populations with respect to blood pressure, heart rate 
and total cholesterol.
The prevalence of the CAC score categories (0 AU, 1–99 
AU, ≥100 AU) were similar for the NSCP and background 
population (46%, 32%, 22% vs 48%, 33% and 19%, 
P=0.630), and there was no difference in the median CAC 
score (2 AU (IQR 0–74 AU) and 1 AU (IQR 0–54 AU), 
P=0.229). We analysed various subgroups, and there were 
similarly no differences in the median CAC scores for 
Table 1 Characteristics of participants and non-
participants
Participants
Non-
participants
P valueN=229 N=212
Age (years) 57 
(56 to 58)
52 
(50 to 53)
0.001
Male 98 (43) 89 (42) 0.86
Diabetes mellitus 22 (10) 10 (5) 0.048
Hypertension 91 (40) 70 (33) 0.14
Hypercholesterolaemia 97 (42) 67 (32) 0.02
Family history 124 (54) 93 (44) 0.03
Smoking 58 (25) 57 (27) 0.71
Values are n (%) or mean (95% CI).
Figure 2 Flow chart for the inclusion of the background population. CAD, coronary artery disease.
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women (0 AU (IQR 0–67 AU) and 0 AU (IQR 0–18 AU), 
P=0.74), men (18 AU (IQR 0–83 AU) and 9 AU (IQR 
0–116 AU), P=0.12) or 50–59 year olds (0 AU (IQR 0–33 
AU) and 0 AU (IQR 0–12.5 AU), P=0.25). However, the 
subgroup of 60–69 year olds had a higher median CAC 
score in the NSCP group compared with the background 
population (47 AU (IQR 0–147 AU) vs 7 AU (IQR 0–110 
AU), P=0.008). In the multivariate logistic regression 
analysis there was no significant difference in CAC in the 
NSCP and background population (OR 0.9 (95% CI 0.6 
to 1.3), P=0.546). The OR for CAC >100 AU was 1.0 (95% 
CI 0.6 to 1.5) P=0.826 (online supplementary tables). In 
52 cases, two independent readers performed the CAC 
score measurement; the Pearson’s correlation was 99%.
During 1 year of follow-up, 2 out of 229 patients with 
NSCP underwent cardiac revascularisation, while none 
had UAP, MI, VT or death related to cardiac causes. Of 
the two patients who underwent cardiac revascularisation, 
one was a woman aged 64 years with a CAC score of 340, 
and the other patient was a male aged 60 years with a CAC 
score of 2595. Both were known to have hypertension, 
hypercholesterolaemia and a significant family history of 
CVD. The event rate in the background population was 
4 out of 722, with all of the involved patients were male: 
two had an MI, one had VT and one had a cardiac-related 
death. The patient with VT was 50 years old and had a 
CAC=0, but a significant family history of CVD. The three 
remaining patients were 60 years old with CAC scores of 
166, 832 and 1326. One patient was a smoker with hyper-
tension and hypercholesterolaemia, while a second was a 
smoker with diabetes and a family history of CVD. Fisher’s 
exact test showed no statistically difference in the inci-
dence of endpoints between NSCP and the background 
population (0.9% (95% CI 0.1 to 2.9) vs 0.6% (95% CI 0.2 
to 1.3), P=0.64).
A further 211 patients were referred for cardiac testing 
at the time of index contact and were not included in this 
study. Of those, 152 had a cardiac CT, 26 were referred 
for coronary angiography and 33 for myocardial perfu-
sion scintigraphy. After 1 year of follow-up, two of these 
patients had UAP, two had an MI and nine had coronary 
revascularisation. No one had VT or died from cardi-
ac-related causes. In total, 11 out of 211 patients (5.2% 
(95% CI 2.8 to 8.9)) had an event, a rate that was signifi-
cantly higher compared with the NSCP and background 
populations (P=0.001).
DIsCussIOn
This is the first study to our knowledge to evaluate the 
role of non-contrast CT in an NSCP population.
We demonstrated that CAC can be detected in approx-
imately half of patients with NSCP, a prevalence that 
does not differ significantly from what can be found in 
the general population. Furthermore, the prognosis for 
patients with NSCP does not differ from the prognosis 
in an asymptomatic background population. However, 
a comparison of patients with NSCP and a background 
population with those referred for cardiac investigation 
showed that the latter group has a significantly higher 
rate of clinical events. As the CAC score in patients with 
NSCP does not differ from the general population, we do 
not consider non-contrast CT scanning a useful risk strat-
ification tool for patients with NSCP. It appears to be of 
limited value for patients with NSCP, and moreover may 
lead to increased downstream test utilisation.
Laudon et al17 showed that in patients with non-cardiac 
chest pain presenting to the emergency department and 
fulfilling the criteria for UAP, the prevalence of CAC is 
49%, which is consistent with our findings in patients with 
Table 2 Descriptive characteristics of patients with non-
specific chest pain and the background population
Patients 
with NSCP 
Background 
population
P valueN=229 N=722
Male 98 (43) 295 (45) 0.48
Age (years) 57±9 55±5 0.008
  30–39 7 (3) – 0.001
  40–49 46 (20) –
  50–59 76 (33) 316 (44)
  60–70 100 (44) 406 (56)
Hypertension 91 (40) 266 (37) 0.460
Hypercholesterolaemia 97 (42) 126 (18) 0.001
Diabetes 22 (10) 59 (8) 0.51
Family history of CVD 124 (54) 287 (40) 0.001
Smoking 58 (25) 314 (44) 0.001
Previous smoker 74 (32) 197 (27) 0.142
Non-smoker 97 (42) 211 (29) 0.001
Systolic blood 
pressure (mm Hg)
144±30 137±19 0.001
Diastolic blood 
pressure (mm Hg)
97±122 83±10 0.002
Heart rate 74±14 71±14 0.001
Total cholesterol 
(mmol/L)
5.2±1.1 5.5±1.1 0.005
LDL cholesterol 
(mmol/L)
3.1±0.9 3.2±0.9 0.070
HDL cholesterol 
(mmol/L)
1.4±0.5 1.5±0.5 0.080
BMI (kg/m2) 27±6 27±5 0.715
CAC score (AU) 2 (0–74) 1 (0–54) 0.229
  0 106 (46) 350 (48) 0.679
  1–99 74 (32) 238 (33) 0.897
  ≥100 49 (22) 134 (19) 0.438
Values are n (%), mean±SD or median (IQR).
AU, Agatston unit; BMI, body mass index; CAC, coronary artery 
calcification; CVD, cardiovascular disease; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; NSCP, non-specific chest 
pain.
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NSCP. In Laudon’s study, patients with non-cardiac 
chest pain with a CAC=0 had a 100% 5 year probability 
of event-free survival. This was significantly better than 
for the cardiac-related chest pain group, which implies 
that a non-contrast CT scan may be useful in discrimi-
nating between non-cardiac-related and cardiac-related 
chest pain. However, the study by Laudon et al included 
patients fulfilling the criteria for unstable angina, who 
were scanned during the index contact. Thus, this patient 
population was at higher risk of CVD compared with the 
patients in our study, who were not referred for further 
cardiac investigations after the index contact.
The Society of Cardiovascular Computed Tomog-
raphy Guidelines recommends referring patients for a 
coronary CT angiography (which also visualises the arte-
rial lumen), if they present to the emergency depart-
ment with acute chest pain, a negative ECG, normal 
biomarkers, a low to intermediate pretest likelihood by 
risk stratification and no identifiable coronary cause for 
their chest pain.18 In the present study, we found that 
patients who met these guideline criteria had a 1-year 
event rate of 5%, as opposed to the approximately 1% 
1-year event rate found in patients with NSCP for whom a 
clinical assessment does not suggest a need for additional 
diagnostic testing. While we did not perform CT angiog-
raphy, we found that the presence of CAC in patients with 
NSCP did not differ from the background population. 
Thus, clinical assessments, with respect to risk-stratifying 
patients with NSCP for further testing, appear to be accu-
rate. The differences in characteristics between those 
referred for further investigations and those included 
in our study without referral at index contact were not, 
however, explored in this study.
In our study, it was not possible to reach a conclusion 
on the prognostic value of CAC in predicting adverse 
cardiac events, largely due to the small number of 
study events, the short time to follow-up and the small 
number of participants. However, it is worth noting that 
both of the patients in the NSCP study population who 
had clinical events had very high CAC scores (349 and 
2595), and both had three risk factors for CVD (hyper-
tension, hypercholesterolaemia and a family history of 
CVD). This finding agrees with previous studies that 
have demonstrated that a high CAC score is a major 
and independent CVD risk factor.19 In concordance 
with previous studies, we found a very low event rate 
in patients without CAC.20 In the NSCP population, 
no cardiac events among patients with a CAC=0 were 
observed, while one person in the background popula-
tion had VT and a CAC=0.
The NSCP population included more patients with 
hypercholesterolaemia compared with the background 
population (43% vs 18%). We know from previous studies 
that NSCP is associated with frequent contact with the 
healthcare system and higher medication use.21 This 
could partially explain why more patients in this group 
were diagnosed with hypercholesterolaemia.
strengths/limitations
The outcome data collected from the Danish registries 
are well documented and validated, which adds strength 
to this study.22 23 The participants in this study and in 
the background population are likely healthier than the 
non-participants, with clinical trials involving the latter 
group demonstrating that they are at higher risk and 
have worse outcomes.24 The patients with NSCP and the 
background population were preselected to exclude indi-
viduals without risk factors as well as those with known 
CAD or coronary angiography within the last 5 years. 
Thereby, the results are not applicable to very-low-risk 
and high-risk patients, for whom risk stratification is a 
less relevant element of care. We know from previous 
validation studies that the self-reported data for CVD are 
under-reported and inaccurate compared with measured 
data.25 26 A sensitivity of 84.5% has been shown for hyper-
tension, hypercholesterolaemia and diabetes.25 This may 
have influenced the selection of our patients, since the 
presence of risk factors was an inclusion criteria. Patients 
who at index admission were referred for further inves-
tigations were not included in this study. They could 
have a higher prevalence of CAC that again would not be 
accounted for in this study.
The definition of risk factors varied between the 
study participants and the DanRisk comparator group. 
Family history was limited by age in the DanRisk study, 
whereas there was no age limit for patients with NSCP. 
This may explain the higher proportion of patients 
with a family history of CAD among patients with NSCP. 
Furthermore, the way that data was gathered differed: 
for patients with NSCP the values were extracted from 
an acute setting, while in contrast the DanRisk patients 
were investigated in a baseline examination (ie, the 
blood pressures were not obtained uniformly and thus 
not comparable).
The scanners and protocols that were used in the two 
studies differed, and this may have affected measure-
ments of the presence of CAC. However, the centres and 
scanners used for the CAC assessment in the patients with 
NSCP and background population were almost the same 
and comparable for that reason.
Finally, the study was underpowered to show any differ-
ences in cardiac events. It is thus an observational study 
characterising the prevalence of CAC in patients with 
NSCP.
COnClusIOn
When adjusted for traditional CVD risk factors, the results 
of this study show that the presence of CAC in patients with 
NSCP does not significantly differ significantly from a 
background population. Specifically, a little more than 
half of patients with NSCP have detectable CAC on a 
cardiac CT scan. The prognosis for patients with NSCP 
appears to no worse than a background population with a 
combined cardiac event rate of <1%.
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